Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
AMLX Analyst Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AMLX Stock 12 Month Forecast
Average Price Target
$11.38
▲(38.78% Upside)
| Highest Price Target$17.00 | Average Price Target$11.38 | Lowest Price Target$8.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$8.5→$8
Hold
-2.44%
Downside
Reiterated
08/12/25
H.C. Wainwright
$16
Buy
95.12%
Upside
Reiterated
08/08/25
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide's AdvancementsValuation and Risks. Our price target of $16 is based on an equally weighted composite of: (a) $18.49/ share, as a 20x multiple of taxed and diluted 2034 EPS of $2.56/share discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $13/share, with a discount rate of 11% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.
Leerink Partners
$10
Buy
21.95%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and Cormedix (NASDAQ: CRMD)We remain bullish on the avexitide data next year and that is where we think investors should remain focused. However, we look forward to the unblinded Phase 1b PSP data and the early data from the ALS program in 2025, which both have good risk/reward opportunity, given the minimal if any expectations in the investment community. We reiterate our Outperform rating and $10 PT.
TD Cowen
―
Buy
―
Reiterated
08/07/25
Bank of America Securities
$10
Buy
21.95%
Upside
Reiterated
07/23/25
Goldman Sachs
$10
Buy
21.95%
Upside
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Citi
$12
Buy
46.34%
Upside
Reiterated
07/14/25
Guggenheim
$17
Buy
107.32%
Upside
Initiated
06/24/25
Mizuho Securities
$7→$8
Buy
-2.44%
Downside
Reiterated
05/14/25
Robert W. Baird
$3→$11
Buy
34.15%
Upside
Upgraded
11/18/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$8.5→$8
Hold
-2.44%
Downside
Reiterated
08/12/25
H.C. Wainwright
$16
Buy
95.12%
Upside
Reiterated
08/08/25
Promising Market Potential and Financial Outlook for Amylyx Pharmaceuticals Inc. Driven by Avexitide's AdvancementsValuation and Risks. Our price target of $16 is based on an equally weighted composite of: (a) $18.49/ share, as a 20x multiple of taxed and diluted 2034 EPS of $2.56/share discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $13/share, with a discount rate of 11% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of an early developmental-stage biopharmaceutical company.
Leerink Partners
$10
Buy
21.95%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and Cormedix (NASDAQ: CRMD)We remain bullish on the avexitide data next year and that is where we think investors should remain focused. However, we look forward to the unblinded Phase 1b PSP data and the early data from the ALS program in 2025, which both have good risk/reward opportunity, given the minimal if any expectations in the investment community. We reiterate our Outperform rating and $10 PT.
TD Cowen
―
Buy
―
Reiterated
08/07/25
Bank of America Securities
$10
Buy
21.95%
Upside
Reiterated
07/23/25
Goldman Sachs
$10
Buy
21.95%
Upside
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Citi
$12
Buy
46.34%
Upside
Reiterated
07/14/25
Guggenheim
$17
Buy
107.32%
Upside
Initiated
06/24/25
Mizuho Securities
$7→$8
Buy
-2.44%
Downside
Reiterated
05/14/25
Robert W. Baird
$3→$11
Buy
34.15%
Upside
Upgraded
11/18/24
Best Analysts Covering Amylyx Pharmaceuticals Inc
1 Month
xxx
Success Rate
10/20 ratings generated profit
Average Return
-4.65%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -4.65% per trade.
3 Months
xxx
Success Rate
9/17 ratings generated profit
Average Return
+21.75%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +21.75% per trade.
1 Year
Success Rate
13/20 ratings generated profit
Average Return
+45.29%
reiterated a buy rating 7 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +45.29% per trade.
2 Years
xxx
Success Rate
13/20 ratings generated profit
Average Return
+80.23%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 65.00% of your transactions generating a profit, with an average return of +80.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AMLX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
4
8
10
9
5
Buy
0
1
1
7
8
Hold
7
9
7
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
18
18
25
21
Each month's total comprises the sum of three months' worth of ratings.
AMLX Financial Forecast
AMLX Stock Forecast FAQ
What is AMLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Amylyx Pharmaceuticals Inc’s 12-month average price target is 11.38.
What is AMLX’s upside potential, based on the analysts’ average price target?
Amylyx Pharmaceuticals Inc has 38.78% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AMLX a Buy, Sell or Hold?
Amylyx Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is Amylyx Pharmaceuticals Inc’s price target?
The average price target for Amylyx Pharmaceuticals Inc is 11.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $8.00. The average price target represents 38.78% Increase from the current price of $8.2.
The highest analyst price target is $17.00 ,the lowest forecast is $8.00. The average price target represents 38.78% Increase from the current price of $8.2.
What do analysts say about Amylyx Pharmaceuticals Inc?
Amylyx Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of AMLX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.